PsiOxus meets in Phase II cancer cachexia trial

PsiOxus Therapeutics Ltd. (Abingdon, U.K.) said twice-daily 10 mg oral MT-102 met the primary endpoint of greater weight gain over 16 weeks vs. placebo in the Phase II ACT1 trial to treat cancer cache...